# A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Source: https://onco.cc/trials/nct07011186/  
OnCo record `nct07011186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Azacitidine in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies is a phase 1/2 interventional study registered as NCT07011186 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 138 participants planned, started 2024-04-17 and due to reach its primary completion in 2025-10. Interventions recorded: TQB3909 Tablets + Azacitidine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07011186
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT07011186: https://clinicaltrials.gov/study/NCT07011186

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [TQB3909](https://onco.cc/drugs/tqb3909/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07011186.json